RxDoctor Payments Data

Erik Folch, MD

Pulmonary Disease · Boston, MANPI 1578739231

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $346,812 of the $543,042 with a category attached, or 63.9%. 14 manufacturers reported payments, led by Intuitive Surgical at 55.7% of the total. 2025 is the largest year on record at $154,045, 4.4 times the $35,029 reported in 2019. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$543,042in general payments, 2019–2025

Across 656 payments — averaging $827.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$302K
  • Medtronic$104K
  • Cook Incorporated$42K
  • Boston Scientific$37K
  • Siemens Medical Solutions USA, Inc.$22K
  • Pinnacle Biologics, Inc$19K
  • plus $17K from 8 others
$92,489in research payments, 2019–2025

Across 31 payments — averaging $2983.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intuitive Surgical Operations, Inc.$76K
  • Medtronic$12K
  • Covidien LP$4K

What the payments were for

  • Consulting fees$62,77512%
  • Speaking & faculty fees$346,81264%
  • Travel & lodging$103,53719%
  • Food & beverage$17,8913%
  • Education$12,0142%
  • Gifts$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$543,042 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.

See all pulmonary disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$62,030
Medicare patients
194
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →